S1P receptor antagonists fingolimod and siponimod do not improve the outcome of experimental autoimmune myasthenia gravis mice after disease onset.
about
S1P receptor antagonists fingolimod and siponimod do not improve the outcome of experimental autoimmune myasthenia gravis mice after disease onset.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
S1P receptor antagonists fingo ...... avis mice after disease onset.
@en
S1P receptor antagonists fingo ...... avis mice after disease onset.
@nl
type
label
S1P receptor antagonists fingo ...... avis mice after disease onset.
@en
S1P receptor antagonists fingo ...... avis mice after disease onset.
@nl
prefLabel
S1P receptor antagonists fingo ...... avis mice after disease onset.
@en
S1P receptor antagonists fingo ...... avis mice after disease onset.
@nl
P2093
P2860
P356
P1476
S1P receptor antagonists fingo ...... avis mice after disease onset.
@en
P2093
Falk Hiepe
Hanne Schaffert
Radharani Diallo
Siegfried Kohler
P2860
P356
10.1002/EJI.201747187
P407
P577
2017-12-04T00:00:00Z